Global Parenteral Nutrition-Associated Cholestasis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Parenteral Nutrition-Associated Cholestasis Treatment Market Size

• The Global Parenteral Nutrition-Associated Cholestasis Treatment Market size was valued at USD 7.38 billion in 2024 and is expected to reach USD 11.24 billion by 2032, at a CAGR of 5.4% during the forecast period
• This growth is driven by factors such as the rising incidence of parenteral nutrition-associated cholestasis, increased awareness among clinicians, growing demand for safer lipid formulations, and advancements in diagnostic and monitoring technologies

Parenteral Nutrition-Associated Cholestasis Treatment Market Analysis

• Parenteral nutrition-associated cholestasis (PNAC) refers to a serious liver complication in preterm infants who are being administrated prolonged intravenous nutrition. Parenteral nutrition is defined as lifesaving intervention for many preterm infant’s other neonates suffering from severe illness
• The demand for Parenteral Nutrition-Associated Cholestasis Treatment is significantly driven by the increasing incidence of PNAC in neonates and patients requiring prolonged parenteral nutrition, heightened awareness among healthcare providers, advancements in lipid emulsions, and improved diagnostic and monitoring technologies
• North America is expected to dominate the Global Parenteral Nutrition-Associated Cholestasis Treatment market with a share of 36.4%, owing to its advanced neonatal and pediatric care infrastructure, high awareness among healthcare professionals, and strong presence of leading pharmaceutical and nutrition companies
• Asia-Pacific is projected to be the fastest-growing region in the Global Parenteral Nutrition-Associated Cholestasis Treatment market during the forecast period, driven by expanding healthcare access, increasing investments in neonatal care, and rising awareness of parenteral nutrition-related complications
• The Lipid Injectable Emulsion segment is anticipated to lead the market with a share of 34.5%, due to its essential role in minimizing cholestasis risk during long-term parenteral nutrition therapy. While emerging lipid formulations and novel treatment strategies are under development, traditional lipid emulsions remain the standard of care due to their proven efficacy, cost-effectiveness, and familiarity among clinicians

Report Scope and Parenteral Nutrition-Associated Cholestasis Treatment Market Segmentation

Parenteral Nutrition-Associated Cholestasis Treatment Market Trends

“Shift Toward Fish Oil-Based Lipid Emulsions and Personalized Nutrition Strategies to Mitigate PNAC Risk”

• One prominent trend in Parenteral Nutrition-Associated Cholestasis (PNAC) Treatment is the shift toward fish oil-based lipid emulsions and personalized nutrition strategies
• This shift is driven by increasing clinical evidence linking traditional soybean oil-based lipid emulsions to the development of PNAC in neonates and critically ill patients. Fish oil-based alternatives, rich in omega-3 fatty acids, have demonstrated anti-inflammatory properties and a lower incidence of liver complications

• For instance, healthcare providers are increasingly adopting products like Omegaven by Fresenius Kabi, a fish oil-based intravenous lipid emulsion, which has shown effectiveness in reducing cholestasis in pediatric patients on long-term parenteral nutrition

• This trend is significantly transforming the clinical management of PNAC by reducing liver-related complications, improving patient outcomes, and supporting a more tailored approach to nutrition therapy based on individual metabolic needs and risk profiles
• The PNAC Treatment market is poised for long-term growth, fueled by rising demand for safer lipid alternatives, advancements in nutritional science, and a broader move toward evidence-based, personalized medical nutrition strategies in neonatal and critical care settings

Parenteral Nutrition-Associated Cholestasis Treatment Market Dynamics

Driver

“Rising Incidence of Premature Births and Critically Ill Patients Fuel Demand for Parenteral Nutrition Solutions”

• The increasing technological advancements in Parenteral Nutrition-Associated Cholestasis Treatment are significantly driving the demand for more accurate and efficient diagnostic and surgical tools
• With continuous innovations such as magnetic tracers, radar reflectors, and wireless localization systems, healthcare providers can now offer more precise, non-invasive, and radiation-free alternatives to traditional wire-based localization methods
• As new technologies emerge, the ability to detect and localize small, non-palpable lesions has improved, enhancing the effectiveness of early-stage breast cancer treatment. These advancements enable clinicians to perform more targeted surgeries, minimizing the risk of complications and reducing recovery times for patients
• New technologies also allow for greater flexibility in scheduling procedures, reducing the stress and inconvenience associated with traditional methods. This is particularly important as hospitals and breast care centers aim to streamline operations and improve patient outcomes
• With advancements in imaging and localization technologies, the need for accurate, reliable, and minimally invasive solutions is increasing, ensuring better diagnosis and treatment planning for breast cancer patients. As a result, there is an ongoing shift toward adopting these advanced localization methods in clinical practice

For instance,

• Endomag's Magseed system is a leading magnetic seed localization product that has gained significant traction in the breast cancer surgery space. The product offers a radiation-free, wire-free alternative to traditional methods, providing increased surgical precision and improved patient comfort during procedures

• The rise in technological advancements is expected to continue as more healthcare facilities prioritize the use of cutting-edge tools for better patient outcomes and reduced surgical risks

Opportunity

“High Strategic Partnerships”

• The rising incidence of premature births and critically ill patients is significantly driving the demand for parenteral nutrition solutions
• As the number of premature births and critically ill patients requiring long-term parenteral nutrition increases, there is a greater need for specialized treatment options to prevent complications like Parenteral Nutrition-Associated Cholestasis (PNAC
• This growing patient population is placing a demand on healthcare systems to provide safe, effective, and customized nutrition therapies, particularly for neonates and those with gastrointestinal or liver disorders. Addressing PNAC through targeted lipid emulsions and personalized care is essential to improving the quality of care for these vulnerable patients

For instance,

• Hospitals in the U.S. are increasingly adopting Omegaven®, a fish oil-based lipid emulsion shown to reduce the incidence of PNAC in preterm infants who are dependent on parenteral nutrition for extended periods

• The rising prevalence of premature births and critically ill patients is expected to drive continued growth in the demand for specialized parenteral nutrition therapies, creating a critical need for solutions that can minimize the risks of PNAC while improving patient outcomes
• As healthcare providers focus on enhancing neonatal care and reducing complications in critically ill patients, there will be an increased emphasis on advancing parenteral nutrition strategies to meet the specific nutritional and medical needs of these patients

Restraint/Challenge

“High Costs and Limited Accessibility of Advanced Parenteral Nutrition Therapies Hinder Market Growth”

• The high cost of advanced parenteral nutrition therapies presents a significant challenge for the market, especially in developing regions
• Parenteral nutrition solutions, including specialized lipid emulsions and other treatment modalities to prevent or manage PNAC, can be prohibitively expensive. These costs limit access to advanced treatments, especially in lower-income or resource-constrained areas
• The price of these treatments, coupled with the need for specialized monitoring equipment and skilled medical professionals, can create financial barriers that prevent healthcare systems in developing countries from providing optimal care for at-risk patients

For instance,

• in many low- and middle-income countries, hospitals often struggle to afford high-quality, fish oil-based lipid emulsions like Omegaven, which are essential for reducing the risk of PNAC in premature infants. As a result, healthcare providers in these regions may resort to more affordable, but less effective, soybean oil-based emulsions, which may increase the risk of PNAC

• The financial burden associated with advanced therapies and the need for specialized medical infrastructure can create significant disparities in the availability of effective PNAC treatments, limiting access to care and hindering the growth of the market in underserved regions

Parenteral Nutrition-Associated Cholestasis Treatment Market Scope

The market is segmented on the basis of drug, treatment, mode of administration, distribution channel and end user.

In 2025, the lipid injectable emulsion is projected to dominate the market with a largest share in drug segment

The lipid injectable emulsion segment is expected to dominate the Parenteral Nutrition-Associated Cholestasis Treatment market with the largest share of 34.5% in 2025 due to its widespread clinical adoption, cost-effectiveness, and proven efficacy in managing PNAC in critically ill patients. Despite the development of alternative treatments and newer lipid formulations, traditional lipid emulsions, such as soybean oil-based emulsions, remain a standard option in many healthcare settings. These treatments are well-established, relatively simple to administer, and are familiar to healthcare providers. Their long-standing use in preventing PNAC and managing nutritional support in neonates and patients on extended parenteral nutrition continues to sustain their dominant position in the market.

The Surgery is expected to account for the largest share during the forecast period in treatment segment

In 2025, the Surgery segment is expected to dominate the market due to its established efficacy, cost-effectiveness, and broad clinical adoption. These emulsions, including fish oil-based and soybean oil-based formulations, play a critical role in managing PNAC in patients requiring long-term parenteral nutrition. Despite the emergence of new lipid formulations and therapies, traditional lipid emulsions continue to be the preferred treatment option due to their proven track record in reducing liver complications associated with PNAC. Their widespread use in neonatal and pediatric care, combined with the simplicity of administration and cost-effectiveness, contributes to their market dominance. Furthermore, ongoing clinical research and positive regulatory outcomes continue to support the sustained growth of this segment in the market.

Parenteral Nutrition-Associated Cholestasis Treatment Market Regional Analysis

“North America Holds the Largest Share in the Parenteral Nutrition-Associated Cholestasis Treatment Market”

• North America dominates the Parenteral Nutrition-Associated Cholestasis Treatment market with a share of 36.4%, driven by its advanced healthcare infrastructure, high adoption of innovative lipid emulsions, and the presence of key market players specializing in parenteral nutrition solutions
• The U.S. holds a significant share of 78.3%, primarily due to the increasing demand for advanced lipid emulsions, such as fish oil-based intravenous lipid formulations, to manage PNAC in preterm infants and critically ill patients. The high prevalence of conditions requiring long-term parenteral nutrition further fuels the market’s growth in this region
• The presence of leading companies like Fresenius Kabi, B. Braun, and Omegaven® producers, along with continuous advancements in lipid formulation technologies, continues to drive innovation in PNAC treatment. Significant investment in research and development (R&D) further supports the continuous improvement of nutritional therapies to prevent and manage PNAC
• The increasing prevalence of premature births, along with greater awareness of PNAC risks, supports the market’s growth. As healthcare standards improve and the understanding of PNAC expands, the demand for more effective, safer, and patient-specific lipid emulsions is expected to continue rising, solidifying North America’s dominant position in the market

“Asia-Pacific is Projected to Register the Highest CAGR in the Parenteral Nutrition-Associated Cholestasis Treatment Market”

• The Asia-Pacific region is expected to witness the highest growth rate in the Parenteral Nutrition-Associated Cholestasis Treatment market, driven by rapid healthcare infrastructure development, increasing awareness of neonatal and pediatric nutrition, and rising adoption of parenteral nutrition in clinical settings
• Countries such as China, India, and Japan are emerging as key markets for PNAC treatment due to the growing incidence of premature births and gastrointestinal disorders requiring long-term parenteral nutrition. Increased awareness of PNAC and government-supported neonatal care initiatives are further accelerating demand for effective treatment options
• Japan, with its advanced healthcare infrastructure and emphasis on pediatric care, remains a significant market for PNAC therapies. The country is increasingly adopting improved lipid emulsions and clinical protocols to reduce PNAC incidence and enhance patient outcomes in neonatal intensive care units (NICUs)
• The rising focus on expanding access to critical care and improving nutrition management for vulnerable populations is expected to drive the demand for advanced lipid-based therapies across the APAC region, making it the fastest-growing regional market for PNAC treatment during the forecast period

Parenteral Nutrition-Associated Cholestasis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Teva Pharmaceutical Industries Ltd (Israel)
• Zydus Cadila (India
• ALLERGAN (U.S.)
• Endo Pharmaceuticals Inc. (U.S.)
• ANI Pharmaceuticals, Inc. (U.S.)
• Mylan N.V. (U.S.) (formerly Netherlands, now part of Viatris headquartered in the U.S.)
• Glenmark Pharmaceuticals Ltd (India)
• Amneal Pharmaceuticals LLC (U.S.)
• Epic Pharma, LLC (U.S.)
• Lannett (U.S.)
• Fresenius Kabi AG (Germany) 

SKU-46586